Polyphor announces plans to IPO and list on SIX Swiss Exchange
Polyphor, a clinical-stage biopharmaceutical Company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, intends to conduct an initial public offering (“IPO”) on the SIX Swiss Exchange in Q2 2018. Lead product candidate, murepavadin, now in Phase III, has the potential to lead to a paradigm shift in the fight against Pseudomonas aeruginosa - one of the most dangerous Gram-negative bacteria. Immuno-oncology compound balixafortide, developed by Polyphor, has shown strong results in a Phase 1b/clinical proof of concept trial in advanced metastatic breast cancer in combination with eribulin with a development path identified with the FDA to conduct a single pivotal study for approval.
VISCHER AG is acting as Swiss legal counsel to the issuer with Matthias Staehelin (Partner, Corporate) as team leader, Benedict Christ (Partner, Corporate), Angelo Imperiale (Associate, Corporate), Luzius Zumstein (Associate, Corporate), Nadia Tarolli (Partner, Tax) and Adrian Briner (Associate, Tax).